Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | APEX1 | P27695 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8837544 | 0.85 | MEN1 (0.60) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL29354738 | 0.85 | MEN1 (0.60) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL8837588 | 0.84 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL11982925 | 0.84 | MEN1 (0.58) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL14074266 | 0.83 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL3953151 | 0.79 | KDM4E (0.79) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL3096605 | 0.77 | HSD11B1 (0.57) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL7516951 | 0.77 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1MAPTAPEX1 | |
| SCHEMBL3036074 | 0.76 | KDM4E (0.74) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL9127829 | 0.76 | KDM4E (0.86) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2089381-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269290-A1 | Indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139548-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885ALDH1A1 397/4885 |
| US-20080139617-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885ALDH1A1 397/4885 |
| US-20080269290-A1 | Indoles | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885ALDH1A1 397/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | MEN1 1712/4885KMT2A 1042/4885ALDH1A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.